# IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)

> **NCT00785122** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immatics Biotechnologies GmbH** · enrollment: 92 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** Endoxana, Leukine, IMA910
- **DRUG:** Endoxana, Leukine, IMA910, Aldara

## Key facts

- **NCT ID:** NCT00785122
- **Lead sponsor:** Immatics Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-01
- **Final completion:** 2013-05
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2013-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785122, "IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00785122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*